期刊文献+

伐地那非治疗肺动脉高压的观察与护理

下载PDF
导出
摘要 肺动脉高压(pulmonary arterial hypertension, PAH)是一种以肺小动脉血管重构为特征的恶性肺血管疾病,往往由于肺血管阻力进行性升高并最终导致患者右心力衰竭而死亡。但随着治疗水平的提高和多种药物的应用,肺动脉高压患者的生存率显著延长。
出处 《上海护理》 2012年第5期49-51,共3页 Shanghai Nursing
  • 相关文献

参考文献13

  • 1D' Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospec- tive registry [ J ]. Ann Intern Med, 1991,115 (5) :343-349.
  • 2Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension:prognostic factors and survival[ J]. J Am Coil Cardiol,2002,40(4 ) :780-788.
  • 3Corhin JD, Beasley A, Blount MA, et al. Vardenafil: structural basis for higher potency over sildenafil in inhibiting eGMP-specific phosphodiesterase-5 ( PDE5 ) [ J ]. Neuroehem Int, 2004,45 ( 6 ) : 859-863.
  • 4Ghofrani HA, Pepke-Zaba J, Barbera JA, et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension [J]. J Am Coll Cardiol, 2004,43 (12 Suppls) : 68S-72S.
  • 5Aizawa K, Hanaoka T, Kasai H, et al. Long-term vardenafil thera- py improves hemodynamics in patients with pulmonary hypertension [J]. Hypertens Res, 2006,29(2) :123-128.
  • 6Jing ZC, Jiang X, Wu BX, et al. Vardenafil treatment for patients with pulmonary arterial hypertension: a muhicentre, open-label study[ J]. Heart, 2009, 95 (18) : 1531-1536.
  • 7无.肺动脉高压筛查诊断与治疗专家共识[J].中华心血管病杂志,2007,35(11):979-987. 被引量:275
  • 8Wright PJ. Comparison of phosphodiesterase type 5 ( PDE5 ) inhib- itors [ J ]. Int J Clin Pract, 2006,60 ( 8 ) :967-975.
  • 9Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension[ J]. N Engl J Med, 2005,353 (20) :2148-2157.
  • 10Lipkin DP, Scriven ALl, Crake T, et al. Six minute walking test for assessing exercise capacity in chronic heart failure [ J ]. Br Med J Clin Res Ed, 1986,292 ( 6521 ) :653-655.

二级参考文献42

  • 1涂文婷,杨丽丽,张琴辉,王良兴,龚永生,陈国荣.微小输液微粒对家兔肺动脉压影响的研究[J].中华护理杂志,2004,39(6):451-452. 被引量:11
  • 2荆志成,徐希奇.肺动脉高压现代分类和诊断策略[J].中华心血管病杂志,2004,32(12):1160-1162. 被引量:40
  • 3荆志成.六分钟步行距离试验的临床应用[J].中华心血管病杂志,2006,34(4):381-384. 被引量:98
  • 4熊长明,柳志红,何建国,倪新海,程显声.伊洛前列素治疗肺动脉高压的疗效[J].中国新药杂志,2007,16(12):973-976. 被引量:11
  • 5Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension:updated ACCP evidence-based clinical practice guidelines[J].Chest,2007,131(6) : 1917-1928.
  • 6Engelfriet PM,Duffels MG,Moller T,et al. Pulmonary medal hypertension in adults born with a heart septal defect:the Euro Heart Survey on adult congenital heart disease[J]. Heart,2007,93(6):682-687.
  • 7Olschewski H,Simonneau G,Galie N,et al. Inhaled iloprost for severe Pulmonary hypertension[J]. N Engl J Med,2002,347:322-329.
  • 8Szebeni-J,Baranyi-L,Savay-S,et al.Liposome-induced pulmonary hypertension:properties and mechanism of a complement-mediated pseudoallergic reaction.Am J Physiol Heart Circ Physiol,2000,279(3):1319-1328.
  • 9Proceeding of 3rd World Symposium on Pulmonary Arterial Hypertension. Venice, Italy, June 23-25, 2003. J Am Coll Cardiol, 2004,43(2 Suppl S) : 1S-90S.
  • 10Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest, 2004, 126( Suppl 1 ) : 1 S-92S.

共引文献291

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部